Lilly says retatrutide beat Novo's Ozempic in a diabetes study
Eli Lilly says its "triple-G" drug retatrutide beat Novo Nordisk's Ozempic in a diabetes study, adding to expectations that it will be one of Lilly's biggest growth drivers, STAT…
3 posts ·